Who
Denise Scots-Knight
Director
Company insider
Files Form 4 as: Director, Elanco Animal Health; Chief Executive Officer, Mereo BioPharma Group; Director, OncoMed Pharmaceuticals; Director and 10% owner, Albireo Pharma; Director, Idenix Pharmaceuticals; Director, Viacell.
In numbers
- Trades disclosed
- 73
- Buys
- 1
- Sells
- 17
- Bought
- $1.0M
- Sold
- $4.9M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 19 May 2006
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —4,678 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —12,196 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —4,678 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —12,196 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,035,000 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —345,000 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —480,000 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,035,000 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —345,000 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —480,000 at $0.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —10,314 at $0.00 | filing |
| 25 Jan 2025filed 28 Jan 2025 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —825,000 at $0.00 | filing |
| 29 Nov 2024filed 3 Dec 2024 | ELAN Elanco Animal HealthPharmaceuticals | SEC FORM 4 Code A | —18,169 at $0.00 | filing |
| 13 Sep 2024filed 16 Sep 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Sold | $253K60,046 at $4.22 | filing |
| 12 Sep 2024filed 16 Sep 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Sold | $128K28,611 at $4.47 | filing |
| 11 Sep 2024filed 13 Sep 2024 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code M | —188,060 at $0.00 | filing |
| 11 Sep 2024filed 13 Sep 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Code M | —188,060 at $0.00 | filing |
| 26 Jun 2024filed 27 Jun 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Sold | $313K92,273 at $3.39 | filing |
| 25 Jun 2024filed 27 Jun 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Sold | $150K40,712 at $3.69 | filing |
| 21 Jun 2024filed 25 Jun 2024 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code M | —282,090 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.